biostudies-literatureUnknown73Chang L<h4>Background</h4>Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment.<h4>Methods</h4>This single-center, phase 2 prospective study enrolled 13 newly diagnosed and 10 recurrent RDD patients from June 2021 to March 2023 at Peking Union Medical College Hospital (Beijing, China). Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22 was administered in 28-day cycles, totaling 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to lenalidomide and dexamethasone (RD) regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. OS and PFS were estimated according to Kaplan-Meier survival analysis and compared wiEClinicalMedicine102685https://www.ebi.ac.uk/biostudies/studies/S-EPMC11253284biostudies-literatureLenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study.PMC11253284Zhou DBLang MCao XXChang LLiu ZZLin HLiu TCai HfalseLenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study.<h4>Background</h4>Rosai-Dorfman disease (RDD) is a rare heterogeneous histiocytic disorder lacking standardized first-line treatment.<h4>Methods</h4>This single-center, phase 2 prospective study enrolled 13 newly diagnosed and 10 recurrent RDD patients from June 2021 to March 2023 at Peking Union Medical College Hospital (Beijing, China). Lenalidomide 25 mg days 1-21 plus dexamethasone 40 mg days 1, 8, 15, 22 was administered in 28-day cycles, totaling 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall response rate (ORR) to lenalidomide and dexamethasone (RD) regimen, toxicity, and overall survival (OS) measured from RD start to death or last follow-up. OS and PFS were estimated according to Kaplan-Meier survival analysis and compared wi2024-01-01T00:00:00Z2024 Jul2026-06-02T11:51:39.15Z2025-04-06T17:10:41.752ZS-EPMC112532843902279610.1016/j.eclinm.2024.102685